bioAffinity Technologies, Inc.(BIAF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BIAF bioAffinity Technologies, Inc.

Trading 05-18 09:49:02 EDT

1.78

-0.10

-5.59%

High1.86	Low1.78	Vol13.35K
Open1.84	D1 Closing1.88	Amplitude4.52%
Mkt Cap7.99M	Tradable Cap6.04M	Total Shares4.50M
T/O24.22K	T/O Rate0.39%	Tradable Shares3.40M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BIAF","market":"US","secType":"STK","nameCN":"bioAffinity Technologies, Inc.","latestPrice":1.775,"timestamp":1779112129595,"preClose":1.88,"halted":0,"volume":13345,"delay":0,"changeRate":-0.055851063829787224,"floatShares":3401400,"shares":4498700,"eps":-11.3182,"marketStatus":"Trading","change":-0.105,"latestTime":"05-18 09:49:02 EDT","open":1.84,"high":1.86,"low":1.775,"amount":24218.8382905,"amplitude":0.045213,"askPrice":1.78,"askSize":498,"bidPrice":1.77,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-11.3182,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1779134400000},"marketStatusCode":2,"adr":0,"listingDate":1662004800000,"exchange":"NASDAQ","adjPreClose":1.88,"preHourTrading":{"tag":"盘前","latestPrice":1.82,"preClose":1.88,"latestTime":"09:22 EDT","volume":1035,"amount":1847.987946,"timestamp":1779110578944,"change":-0.06,"changeRate":-0.031915,"amplitude":0.06383},"postHourTrading":{"tag":"盘后","latestPrice":1.87,"preClose":1.88,"latestTime":"19:20 EDT","volume":2803,"amount":5277.4398,"timestamp":1778887245443,"change":-0.01,"changeRate":-0.005319,"amplitude":0.021277},"volumeRatio":1.018792},"requestUrl":"/m/hq/s/BIAF/wiki","defaultTab":"wiki","newsList":[{"id":"2634212387","title":"bioAffinity reports April CyPath Lung unit sales jump nearly 300% year over year","url":"https://stock-news.laohu8.com/highlight/detail?id=2634212387","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634212387?lang=en_us&edition=fundamental","pubTime":"2026-05-12 21:15","pubTimestamp":1778591726,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies reported record monthly unit sales for CyPath Lung in April 2026, based on preliminary unaudited data.CyPath Lung unit sales rose nearly 300% from April 2025, exceeding internal projections.Growth was attributed to accelerating physician adoption, expansion of ordering sites, and deeper integration into clinical workflows for lung cancer risk assessment and pulmonary nodule management.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL8NgjkW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633545988","title":"bioAffinity Technologies Q1 EPS $(0.81) Beats $(2.70) Estimate, Sales $1.352M Miss $1.553M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633545988","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633545988?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:38","pubTimestamp":1778243880,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies (NASDAQ:BIAF) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(2.70) by 70 percent. This is a 83.13 percent increase over losses of $(4.80) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52406453/bioaffinity-technologies-q1-eps-0-81-beats-2-70-estimate-sales-1-352m-miss-1-553m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633456768","title":"bioAffinity Technologies Inc - Total Consolidated Revenue Decreases 27% to $1.4 Mln in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633456768","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633456768?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:32","pubTimestamp":1778243547,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nFWN41L19B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAF","BIAFW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145675","title":"bioAffinity Technologies Inc - Q1 2026 Net Loss $3.6 Mln or $0.81 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145675","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145675?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:32","pubTimestamp":1778243547,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nFWN41L19B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAFW","BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633456746","title":"bioAffinity Q1 FY26 net loss widens to $3.6 million; revenue drops 27% to $1.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633456746","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633456746?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:31","pubTimestamp":1778243470,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies posted Q1 2026 revenue down 27% to USD 1.4 million.Net loss widened to USD 3.6 million, or USD 0.81 per share.CyPath Lung testing revenue rose 114% to USD 361,000, while CyPath Lung unit sales climbed 146% year over year.Operating expenses increased to USD 5 million from USD 4.5 million, driven by selling, general and administrative costs rising to USD 3.2 million from USD 2.5 million.Launched a Department of Defense-backed longitudinal CyPath Lung trial expected to include up to 20 clinical sites; management said 2026 focus remains scaling commercialization, expanding into new geographic markets, and driving higher utilization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. publis","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDLvfHrh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633290456","title":"Press Release: bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath(R) Lung","url":"https://stock-news.laohu8.com/highlight/detail?id=2633290456","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633290456?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:30","pubTimestamp":1778243400,"startTime":"0","endTime":"0","summary":"CyPath Lung cancer diagnostic unit sales rise 146% year-over-year. Growth expected to accelerate throughout 2026 as planned commercial initiatives seek to drive increasing awareness of CyPath Lung benefits. bioAffinity Technologies, Inc. , a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the first quarter ended March 31, 2026.--  CyPath Lung unit sales increased 146% year-over-year in the first. quarter of 2026, reflecting accelerating physician adoption and expanding. clinical use of the Company's noninvasive lung cancer diagnostic.--  CyPath Lung testing revenue increased approximately 114% to. $361,000, compared to $169,000 in the first quarter of 2025.--  Total consolidated revenue decreased approximately 27% to $1.4 million,compared to $1.9 million for the first quarter of 2025, resulting from. the discontinuation of certain unprofitable pathology s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","R","BK4139","BK4232","BK4022","CLIA","NPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632662437","title":"bioAffinity Technologies shareholders approve equity plan share reserve increase to 1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2632662437","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632662437?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:51","pubTimestamp":1777585892,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies held its annual stockholder meeting on April 30, 2026.Stockholders adopted an amendment to bioAffinity’s 2024 Equity Incentive Compensation Plan, raising shares reserved for issuance under plan to 1,000,000 from 66,666.Investors ratified WithumSmith+Brown, PC as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL86hKx2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632664214","title":"BioAffinity Technologies files to sell 497,483 shares of common stock for holder","url":"https://stock-news.laohu8.com/highlight/detail?id=2632664214","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632664214?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:19","pubTimestamp":1777583980,"startTime":"0","endTime":"0","summary":"17:09 EDT BioAffinity Technologies (BIAF) files to sell 497,483 shares of common stock for holder Published first on TheFly – the ultimate source f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-files-to-sell-497483-shares-of-common-stock-for-holder-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-files-to-sell-497483-shares-of-common-stock-for-holder-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630758372","title":"BioAffinity Technologies launches new study to expand use of CyPath lung tech","url":"https://stock-news.laohu8.com/highlight/detail?id=2630758372","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630758372?lang=en_us&edition=fundamental","pubTime":"2026-04-28 22:04","pubTimestamp":1777385045,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies (BIAF) announced a pilot study with Brooke Army Medical Center, BAMC, to evaluate the Company’s proprietary tests under de...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-launches-new-study-to-expand-use-of-cypath-lung-tech-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-launches-new-study-to-expand-use-of-cypath-lung-tech-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630848300","title":"bioAffinity launches pilot study with Brooke Army Medical Center for asthma, COPD tests","url":"https://stock-news.laohu8.com/highlight/detail?id=2630848300","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630848300?lang=en_us&edition=fundamental","pubTime":"2026-04-28 21:20","pubTimestamp":1777382441,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies launched a pilot clinical study with Brooke Army Medical Center to evaluate sputum-based tests under development for asthma and COPD.Results have not been presented; study will use automated analysis to identify inflammatory biomarkers intended to guide treatment selection and monitor therapy response.Enrollment targets about 40 participants across asthma, COPD, and healthy control cohorts.Program expands CyPath Lung platform beyond lung cancer into airway disease, targeting an asthma and COPD treatment market estimated at $92 billion.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDLbwTTHw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627445570","title":"bioAffinity releases case study on CyPath Lung test guiding nodule follow-up imaging","url":"https://stock-news.laohu8.com/highlight/detail?id=2627445570","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627445570?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:01","pubTimestamp":1776168094,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies released a new clinical case study on CyPath Lung, its noninvasive sputum-based lung cancer diagnostic.Results have already been presented in the case study release.CyPath Lung delivered a negative result that supported a physician decision to order follow-up imaging instead of proceeding directly to biopsy.Subsequent imaging showed the suspicious lung finding had resolved, supporting an inflammatory explanation rather than cancer.Management framed CyPath Lung as a decision-support tool that can help defer unnecessary invasive procedures in high-risk patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL8xQnMH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625930595","title":"bioAffinity to present CyPath Lung test at Cleveland Clinic early lung cancer symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2625930595","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625930595?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:01","pubTimestamp":1775563300,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies to present CyPath Lung at Cleveland Clinic “Advances in Early Lung Cancer Detection” symposium on April 16, 2026, in Cleveland, Ohio.Chief Medical Officer Gordon Downie to join panel on lung nodule management, highlighting CyPath Lung use in high-risk patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire  on April 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL81Mj0q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624001513","title":"BioAffinity’s CyPath Lung Test unit sales surged 146% y/y in Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=2624001513","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624001513?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:15","pubTimestamp":1775045744,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies (BIAF) announced that unit sales for its CyPath Lung diagnostic in the first quarter of 2026 exceeded internal projections...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioaffinitys-cypath-lung-test-unit-sales-surged-146-y-y-in-q1-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioaffinitys-cypath-lung-test-unit-sales-surged-146-y-y-in-q1-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624513351","title":"bioAffinity CyPath Lung unit sales jump 146% in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2624513351","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624513351?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:02","pubTimestamp":1775044964,"startTime":"0","endTime":"0","summary":"bioAffinity posted 146% year-over-year growth in Q1 2026 unit sales for CyPath Lung, based on preliminary unaudited data.US addressable market for pulmonary nodule management and lung cancer survivor surveillance was estimated at USD 3.58 billion.Projected US indeterminate pulmonary nodule volume was forecast to rise 62% to 4.7 million by 2030 from 2.9 million in 2025.Estimated lung cancer survivor population was projected to increase to more than 871,000 by 2030 from 680,000.CyPath Lung revenue rose 87% in 2025; test units sold increased 99% versus 2024.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL5nzSmF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622077464","title":"What's Going On With bioAffinity Technologies Stock Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2622077464","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622077464?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:51","pubTimestamp":1774450260,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies Inc  shares are trading higher on Wednesday. The move follows an announcement regarding a new clinical education initiative.The company plans to host a live virtual physician roundtable on April 8. This event kicks off the “CyPath Lung in Practice” webinar series.A panel of pulmonologists will discuss integrating the noninvasive CyPath Lung test into clinical practice. They will share real-world patient cases.The focus remains on diagnosing indeterminate pulmonary nodules with greater certainty.Participating physicians will demonstrate how the test guides clinical paths. Cases include identifying Stage 1A lung cancer.The test also helps prevent “unnecessary invasive, risky and costly procedures,” according to the company. This occurs when CyPath Lung returns an “Unlikely” malignancy result.The news builds on recent growth. In 2025, CyPath Lung revenue rose 87% year-over-year. The number of tests performed jumped 99%. Management is currently moving away from low","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/25/The-Growth-Of-Prediction-Markets.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/25/The-Growth-Of-Prediction-Markets.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51458941/whats-going-on-with-bioaffinity-technologies-stock-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51458941/whats-going-on-with-bioaffinity-technologies-stock-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4217","SMA","BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622307369","title":"bioAffinity Technologies to host live virtual physician roundtable; CyPath Lung adoption grows in pulmonary practice discussion","url":"https://stock-news.laohu8.com/highlight/detail?id=2622307369","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622307369?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:02","pubTimestamp":1774440176,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies to host live virtual physician roundtable; CyPath Lung adoption grows in pulmonary practice discussion. bioAffinity Technologies will host a live Zoom webinar, “CyPath Lung in Practice: A Physician Roundtable Discussion,” on Wednesday, April 8, 2026, at 7 p.m. ET/6 p.m. CT.Gordon Downie will moderate the session, with panelists Sai Karan Vamsi Guda, Michael Nicholson, and Gregory White.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire  on March 25, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL4ZNcqh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620755504","title":"Why Is bioAffinity Technologies Stock Surging Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620755504","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620755504?lang=en_us&edition=fundamental","pubTime":"2026-03-17 22:32","pubTimestamp":1773757920,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies (BIAF) stock surges Tuesday after a new case study confirms CyPath Lung's role in noninvasive cancer diagnostics. Details here.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/17/Cancer---Heart-Shape-To-Represent-Medica.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/17/Cancer---Heart-Shape-To-Represent-Medica.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51298914/why-is-bioaffinity-technologies-stock-surging-tuesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51298914/why-is-bioaffinity-technologies-stock-surging-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620313421","title":"bioAffinity Technologies releases CyPath Lung case study highlighting 92% sensitivity in nodules under 20 mm","url":"https://stock-news.laohu8.com/highlight/detail?id=2620313421","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620313421?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:45","pubTimestamp":1773747915,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies released a new clinical case study on its CyPath Lung noninvasive lung cancer test in a high-risk patient with multiple pulmonary nodules. The case study described a 71-year-old former smoker whose CyPath Lung result was “Unlikely Malignancy,” and the physician opted to wait for a follow-up CT scan rather than proceed to an invasive biopsy. A follow-up scan in October 2025 showed the suspicious nodules had resolved, while another small nodule remained unchanged. Separately, the company cited results from a clinical study that have already been presented, reporting 92% sensitivity and 87% specificity for detecting lung cancer in nodules smaller than 20 mm.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL8tshWV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619114727","title":"BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2619114727","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619114727?lang=en_us&edition=fundamental","pubTime":"2026-03-14 01:54","pubTimestamp":1773424469,"startTime":"0","endTime":"0","summary":"BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen BioWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL6N4010OX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRCD","ICRC","INMD","VACH","CVNA","CVNX","FITB","CRVS","CMCT","PAR","BW","BIAF","SVCO","AIFF","CRCO","DOUG","ARES","HBAN","ISPC","OFRM","IBG","SDHC","IMM.AU","LVWR","ADBG","ULTA","TVGN","INDV","RJF","KLC","AMAT","PODD","AMPY","CRCA","WDCX","KYIV","CCUP","KLAR","VEON","ESQ","CVNY","SANA"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2619115310","title":"bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2619115310","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619115310?lang=en_us&edition=fundamental","pubTime":"2026-03-13 22:30","pubTimestamp":1773412200,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies shares are trading higher Friday after it reported FY25 results with strong growth in CyPath Lung diagnostic.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/13/Mystery-Rise-In-Otherwise-Healthy-Young-.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/13/Mystery-Rise-In-Otherwise-Healthy-Young-.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51242196/bioaffinity-technologies-stock-soars-120-on-cypath-lung-sales-growth","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51242196/bioaffinity-technologies-stock-soars-120-on-cypath-lung-sales-growth","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4139","BIAF","RSI","BK4150"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bioaffinitytech.com;ir.bioaffinitytech.com","stockEarnings":[{"period":"1week","weight":-0.0739},{"period":"1month","weight":-0.3584},{"period":"3month","weight":0.8077},{"period":"6month","weight":0.0217},{"period":"1year","weight":-0.6952},{"period":"ytd","weight":0.5932}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.125018},{"month":2,"riseRate":0.25,"avgChangeRate":-0.070787},{"month":3,"riseRate":0.5,"avgChangeRate":0.528916},{"month":4,"riseRate":0.75,"avgChangeRate":0.175283},{"month":5,"riseRate":0,"avgChangeRate":-0.182416},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.024762},{"month":7,"riseRate":0.666667,"avgChangeRate":0.072762},{"month":8,"riseRate":0,"avgChangeRate":-0.216971},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.17769},{"month":10,"riseRate":0.25,"avgChangeRate":-0.105345},{"month":11,"riseRate":0.25,"avgChangeRate":-0.068737},{"month":12,"riseRate":0,"avgChangeRate":-0.246482}],"exchange":"NASDAQ","name":"bioAffinity Technologies, Inc.","nameEN":"bioAffinity Technologies, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"bioAffinity Technologies, Inc.(BIAF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest bioAffinity Technologies, Inc.(BIAF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"bioAffinity Technologies, Inc.,BIAF,bioAffinity Technologies, Inc.股票,bioAffinity Technologies, Inc.股票老虎,bioAffinity Technologies, Inc.股票老虎国际,bioAffinity Technologies, Inc.行情,bioAffinity Technologies, Inc.股票行情,bioAffinity Technologies, Inc.股价,bioAffinity Technologies, Inc.股市,bioAffinity Technologies, Inc.股票价格,bioAffinity Technologies, Inc.股票交易,bioAffinity Technologies, Inc.股票购买,bioAffinity Technologies, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"bioAffinity Technologies, Inc.(BIAF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest bioAffinity Technologies, Inc.(BIAF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction